In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
Background: There is a novel hypothesis in that antibodies may have specificity for two distinct antigens that have been named "dual specificity." This hypothesis was evaluated for some defined therapeutic monoclonal antibodies (mAbs) such as Trastuzumab, Pertuzumab, Bevacizumab, and Cetux...
Main Authors: | Soudabeh Akbarzadeh-Sharbaf, Bagher Yakhchali, Zarrin Minuchehr, Mohammad Ali Shokrgozar, Sirous Zeinali |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2012-01-01
|
Series: | Advanced Biomedical Research |
Subjects: | |
Online Access: | http://www.advbiores.net/article.asp?issn=2277-9175;year=2012;volume=1;issue=1;spage=21;epage=21;aulast=Akbarzadeh-Sharbaf |
Similar Items
-
TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin® and US‐Herceptin® in healthy male subjects
by: Martin Demarchi, et al.
Published: (2021-08-01) -
Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016-01-01) -
Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018-09-01) -
Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice
by: Yousif Nasser, et al.
Published: (2011-10-01) -
Trastuzumab – a monoclonal antibody – and dendrimers in a targeted therapy for breast cancer
by: Monika Marcinkowska, et al.
Published: (2015-01-01)